Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine Isabella Ciccone, MPH

Published Date: 02 Dec 2025

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Boom in ADHD Coaching Has Few Rules

2.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

3.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

4.

Medicaid expansion tied to smaller declines in early-stage cancer detection

5.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot